Title : Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study.

Pub. Date : 2014 May

PMID : 25876471






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 RESULTS: Both fingolimod doses significantly reduced annualized relapse rate in patients that received prior interferon-beta or glatiramer acetate, discontinued prior disease-modifying therapy owing to unsatisfactory therapeutic effect, were treatment-naive, or had prior disease-modifying therapy duration of >1-3 years (P<=0.0301 for all comparisons vs placebo). Fingolimod Hydrochloride interferon beta 1 Homo sapiens